Electrocatalytic Drug Metabolism by CYP2C9 Bonded to A Self-Assembled Monolayer-Modified Electrode

Mingli Yang, Jarod L. Kabulski, Lance Wollenberg, Xinqi Chen, Murali Subramanian, Timothy S. Tracy, David Lederman, Peter M. Gannett, and Nianqiang Wu

Departments of Mechanical and Aerospace Engineering (M.Y., N.W.), Physics (D.L.) and Basic Pharmaceutical Sciences (J.L.K., L.W., P.M.G.), West Virginia University, Morgantown, West Virginia; College of Resources and Environmental Sciences, Chongqing University, Chongqing, China (M.Y.); NUANCE Center, Northwestern University, Evanston, Illinois (X.C.); and Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota (T.S.T., M.S.)

Received November 3, 2008; accepted January 23, 2009

ABSTRACT:

Cytochrome P450 (P450) enzymes typically require the presence of at least cytochrome P450 reductase (CPR) and NADPH to carry out the metabolism of xenobiotics. To address whether the need for redox transfer proteins and the NADPH cofactor protein could be obviated, CYP2C9 was bonded to a gold electrode through an 11-mercaptoundecanoic acid and octanethiol self-assembled monolayer (SAM) through which a current could be applied. Cyclic voltammetry demonstrated direct electrochemistry of the CYP2C9 enzyme bonded to the electrode and fast electron transfer between the heme iron and the gold electrode. To determine whether this system could metabolize warfarin analogous to microsomal or expressed enzyme systems containing CYP2C9, warfarin was incubated with the CYP2C9-SAM-gold electrode and a controlled potential was applied. The expected 7-hydroxywarfarin metabolite was observed, analogous to expressed CYP2C9 systems, wherein this is the predominant metabolite. Current-concentration data generated with increasing concentrations of warfarin were used to determine the Michaelis-Menten constant (Km) for the hydroxylation of warfarin (3 μM), which is in good agreement with previous literature regarding Km values for this reaction. In summary, the CYP2C9-SAM-gold electrode system was able to carry out the metabolism of warfarin only after application of an electrical potential, but in the absence of either CPR or NADPH. Furthermore, this system may provide a unique platform for both studying P450 enzyme electrochemistry and as a bioreactor to produce metabolites without the need for expensive redox transfer proteins and cofactors.

In attempts to obviate the requirement of these redox partners/cofactors for catalysis, P450 enzymes have been immobilized on electrodes so that the electrode supplies electrons to drive the P450 catalytic cycle (Estabrook et al., 1996; Reipa et al., 1997; Gilardi et al., 2002) with effective electrical communication between the electrode and the enzyme being critical (Yang et al., 2008). Direct adsorption of enzymes on bare electrodes, such as gold, platinum, and graphite, results in diminished biocatalytic activity (Habermüller et al., 2000; Joseph et al., 2003; Shumyantseva et al., 2005). Complicating these systems, the active redox site is often deeply embedded in the interior of the enzyme, insulating it from the electrode and impeding electron transfer between the electrode and the redox site of enzyme. Finally, immobilization by direct attachment may impede or prohibit substrate binding or metabolite release through steric constraints (Habermüller et al., 2000; Joseph et al., 2003; Shumyantseva et al., 2005). Various methods for enzyme immobilization have been explored to solve the problems that were caused by direct attachment (Reipa et al., 1997; Gilardi et al., 2002; Joseph et al., 2003; Johnson et al., 2005; Shumyantseva et al., 2005). These methods include immobilizing the enzyme in a polyeon film (Masuda and Fukuda, 1995), entrapping the enzyme in a sol-gel film (Masuda et al., 2000), incorporating the
enzyme into conducting polymer films (Funk et al., 2005), modifying the enzyme with an electrical relay (Hahn and Lieber, 2003), functionalizing the electrode with a biomembrane-like surfactant (Oohdag et al., 2006), and supporting the enzyme in a clay nanoparticle modified electrode (Shumyantseva et al., 2004). However, because these methods do not control enzyme aggregation on the electrode surface, the efficiency of electron transfer to the active site of the enzyme may be reduced (Habermüller et al., 2000; Gilardi et al., 2001; Gilardi and Fantuzzi, 2001; Chen et al., 2002), potentially through altered enzyme conformation.

Enzyme orientation and concentration at the electrode surface are critical to the sensitivity of enzymatic devices (Habermüller et al., 2000; Gilardi et al., 2001; Gilardi and Fantuzzi, 2001), and, thus, regioselectively bonding the enzyme to a preformed, self-assembled monolayer (SAM) has been used to control these factors. For example, alkane-thiol or other thiol-terminated chains covalently bonded to a noble-metal surface and functionalized at the terminus with a group that binds to a specific site of the protein, which have been used to control enzyme binding orientation (Collinson and Bowden, 1992; Pardo-Yissar et al., 2000; Chen et al., 2002). CYP2E1 has been bonded through thiols, both directly or via a cysteine-maleimide linker, to a gold surface although enzyme orientation remained ambiguous (Fantuzzi et al., 2004). Bonding to the N terminus of enzymes provides a more specific alternative than bonding to surface cystines that can result in undesirable orientations of the enzyme. Molecular modeling of CYP2C9, based on its crystal structure (Wester et al., 2004), suggests the presence of lysine residues on the surface, some of which are located near the substrate access channel or purported reductase binding site and thus a less than optimal site for attachment. However, it is hypothesized that attachment of CYP2C9 to a gold surface through the N terminus is more likely based on pKa and steric constraints.

In a previously study (Gannett et al., 2006), we bonded CYP2C9 molecules via the N terminus to the carboxylic acid group of 11-mercaptoundecanoic acid (MUA), resulting in a system with catalytic activity toward substrate. However, this system was still dependent on the presence of NADPH and CPR, both of which are expensive, require continual addition upon extended incubations, and can confound isolation and purification of metabolites. To address these issues, this work has now been extended to realize the direct electrochemistry of the surface-bonded CYP2C9 enzyme and evaluate the electrocatalytic activity of CYP2C9 (absent of both NADPH and CPR) toward the hydrogenation of the CYP2C9 substrate warfarin.

Materials and Methods

Chemicals and Reagents. All chemicals were of analytical reagent grade and were used without further purification. MUA, 1-octanethiol (OT), N-(3-dimethylamino)-propyl-N-ethyl carbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (NHS), fluorioboro, dapsone, NADPH, and warfarin were purchased from Sigma-Aldrich (St. Louis, MO). CYP2C9 was prepared by expression in an Escherichia coli system, isolated, and purified as described previously (Gannett et al., 2006). Cytochrome P450 reductase was purchased from BD Biosciences (San Jose, CA). All electrochemical measurements were made in potassium phosphate-buffered solution [PBS] 40 mM, pH 7.4] containing 154 mM NaCl in Milli-Q water (18.2 MΩ-cm) unless otherwise indicated. Gold-coated glass slides (25 mm × 75 mm) with a 4-nm chromium layer and a 100-nm-thick gold top layer were purchased from EMF Corp. (Ithaca, NY).

Immobilization of CYP2C9 Enzyme on Gold Electrode. Gold-coated glass slides were sonicated in acetone for 5 min, rinsed with deionized water, and then soaked in Piranha solution (98% H2SO4: 30% H2O2; 3:1 v/v) at 80°C for 15 min. (Caution: Piranha solution reacts violently with organic chemicals.) The gold-coated glass slides were then rinsed with deionized water and ethanol and then soaked in an ethanol solution of 8-octanethiol (75 mM) and 11-mercaptopoundecanoic acid (25 mM) for 18 h to allow the SAM to attach to the gold surface. Excess physisorbed thiols were removed by rinsing the SAM-bearing, gold-coated glass slides with absolute ethanol and PBS, three times for each slide. To bond the CYP2C9 to the SAM, the SAM-coated slides were covered with PBS containing 2.0 mM EDC and 5.0 mM NHS for 2 h. The treated slides were then removed from the EDC/NHS solution and immersed in a PBS solution containing 50 mM CYP2C9, 40 μM fluorioboro, and 40 μM dapsone for 24 h. All processes were performed under argon at room temperature. Herein, the gold-coated slide functionalized with a MUA/OT monolayer is abbreviated as MUA/OT-Au, and the MUA/OT-Au sample with attached CYP2C9 is abbreviated as CYP2C9-MUA/OT-Au.

X-Ray Photoelectron Spectroscopy Characterization of Immobilized CYP2C9 Enzyme. X-ray photoelectron spectroscopy (XPS) analysis was performed on the SAM-bearing, gold-coated slides with and without immobilized CYP2C9. The XPS measurements were carried out with an Omicron ESCA Probe (Taunusstein, Germany) equipped with an EA125 energy analyzer. Photoemission was stimulated by monochromatic aluminum K-α radiation (1486.6 eV) with an operating power of 300 W. A low-energy electron flood gun was used for charge neutralization. Survey and high-resolution scans were collected using the pass energies of 50 and 25 eV, respectively. Binding energies of the spectra were referenced to the carbon 1s electron (C 1s) binding energy (284.8 eV).

Electrochemical Measurements. The electrochemical measurements were carried out in a three-electrode electrochemical cell comprised of a platinum wire (1 mm o.d.) counter electrode, an Ag AgCl (3 M KCl) reference electrode, and the CYP2C9-bonded gold electrode (CYP2C9-MUA/OT-Au) as the working electrode. The working electrode surface area was approximately 7 mm2.

Different CYP2C9-MUA/OT-Au working electrodes were prepared, and all yielded comparable results. Likewise, CYP2C9 from several enzyme preparations were used for electrode construction and had no effect on the experimental data. All electrochemical measurements were carried out in an aqueous solution (154 mM NaCl, 40 mM PBS, pH 7.4). Cyclic voltammetry (CV) and amperometry measurements were performed using a potentiostat (Gamry Reference 600; Gamry Instruments, Warminster, PA). For anaerobic experiments, solutions were deoxygenated by purging with nitrogen gas for 60 min before measurements and then blanked under a nitrogen atmosphere during measurement. For the aerobic experiments, the solution was purged with oxygen for 1 min before initial measurements. Oxygen saturation was maintained during measurement. All electrochemical experiments were conducted at ambient temperature (25 ± 1°C).

Determination of Enzyme Surface Coverage and Electron Transfer Rate. For redox-active molecules immobilized on an electrode surface, the peak current (i0) is given by the Laviron equation (Laviron, 1979) (eq. 1):

\[
i_0 = n F A \frac{R T}{4 \pi R} N v = n F D_{\text{en}} \frac{R T}{4 \pi R}
\]

where \( n \) is the number of electrons transferred, \( F \) is Faraday’s constant, \( N \) is the area of the electrode, \( N \) is the number of redox active sites on the surface, \( r \) is the scan rate, \( Q \) is the charge passing through the electrode in coulombs, \( R \) is the gas constant, and \( T \) is the temperature. Equation 1 was used to calculate \( n \) (0.72) by obtaining the slope of the linearly fitted curve of \( i_0 \) versus \( v \). Furthermore, given \( n = 0.72 \), the surface coverage of the CYP2C9 molecules can be calculated (8.0 × 10−13 or 4.8 × 1013 mol/cm2). This number is within a factor of 2 of our previous estimate based on atomic force microscopy (Gannett et al., 2006).

For the immobilized CYP2C9, the electron-transfer rate constant (\( k_\text{e} \)) can be obtained according to eq. 2 in the case of \( n D E_\text{en} < 200 \text{ mV} \) (Laviron, 1979), where \( \alpha \) is the electron transfer coefficient and the other variables are as defined previously.

\[
\log k_\text{e} = \log(1 + \alpha) + \log n F D_{\text{en}} \frac{R T}{2 \pi R} \alpha \left(1 + \frac{\alpha}{(1 - \alpha) RT \alpha} \right)
\]

Electrochemical Determination of CYP2C9-Mediated Kinetics Warfarin Hydroxylation. Cyclic voltammetry measurements were made with the Au-SAM-CYP2C9 electrode in solutions containing warfarin (1, 2.5, 5, 10, 15, 20, 30, and 40 μM) and the potential swept cathodically and anodically. The peak reduction current at each concentration was then fit. The apparent Michaelis-Menten constant (\( K_{\text{m(app)}} \)) and \( i_{\text{max}} \) (functionally equivalent to \( V_{\text{max}} \)) were used to evaluate the kinetics of warfarin (to 7-OH-warfain) catalysis by the bonded enzyme.
CYP2C9 enzyme. These parameters were estimated by the Michaelis-Menten equation (eq. 3), where \( C \) is the warfarin concentration, \( i \) is the current, and \( i_{\text{max}} \) is the maximum current.

\[
i = \frac{i_{\text{max}} \cdot C}{K_{\text{M app}} + C}
\]  

(3)

Controlled Potential Electrolysis of Warfarin and Liquid Chromatography Analysis. Electrocatalytic metabolism was performed on the CYP2C9-MUA/OT-Au electrodes in solutions containing 50 \( \mu \)M warfarin dissolved in 154 mM NaCl and 40 mM PBS (pH 7.4) at a fixed potential of -0.38 V for 2 h. The metabolites were isolated by concentration to dryness of the electrolysis solution, dissolving the resulting solid in 2 ml acetonitrile, filtering, and then concentration to dryness. The resulting solid was dissolved in 200 \( \mu \)l of PBS and spiked with 7-ethoxycoumarin (50 \( \mu \)l of acetonitrile containing 1 \( \mu \)g/ml) as an internal standard. Samples were centrifuged (5 min at 13,000 g), and 200 \( \mu \)l of the supernatant was loaded into liquid chromatography (LC) vials. LC was performed with a Waters Alliance 2965 separations module using a Waters Symmetry column (150 \( \times \) 4.6 mm, 3.6-\( \mu \)m particle size; Waters, Milford, MA), eluting with a 60:40 mixture of 0.5% aqueous phosphoric acid/acetonitrile (1 ml/min), with fluorescence detection (Waters 2475, \( \text{ex} = 320 \text{ nm}, \text{em} = 415 \text{ nm} \) ) and an injection volume of 10 \( \mu \)l. All chromatographic analysis was performed using Empower 2 software (Waters). The peak corresponding to 7-hydroxywarfarin was determined by comparison to a 7-hydroxywarfarin standard obtained from Sigma-Aldrich.

Reconstituted CYP2C9 Enzyme Incubation. Reconstituted CYP2C9 enzyme incubations with warfarin were conducted using enzymes prepared from insect cells infected with recombinant baculovirus containing a human CYP2C9*1 cDNA and rabbit NADPH-P450 reductase. For these incubations, 50 \( \mu \)M warfarin was incubated with 125 nM CYP2C9 in 40 mM potassium phosphate buffer (pH 7.4), 1.6 mM phospholipid in THAM, and 250 nm CPR in total volume of 200 \( \mu \)l. Samples were preincubated for 3 min at 37°C before the addition of 1 mM NADPH (final concentration). Incubations were conducted for 20 min at 37°C and quenched by the addition of acetonitrile containing 7-ethoxycoumarin (50 \( \mu \)l of a 1 \( \mu \)g/ml in acetonitrile) as the internal standard. The incubation mixture was then centrifuged (15 min at 13000g) to pellet proteins. A total of 200 \( \mu \)l of the supernatant was then loaded into LC vials for analysis. Chromatographic detection parameters used were the same as those described above.

Results

Characterization of CYP2C9-Immobilized Gold Electrode. During XPS measurement, the energy from X-ray photons of an incident beam are absorbed by an atom in a molecule or solid, leading to ionization and the emission of a core (inner shell) electron in the s, p, d, and f levels. The binding energies of these core-level electrons are heavily dependent upon the chemical states of the atoms, which chemically shift with the coordination environment. Therefore, the binding energies of these core-level electrons are heavily dependent upon the chemical states of the atoms, which chemically shift with the coordination environment. The binding energies of these core-level electrons are used for analysis of the chemical structure. Figure 1a shows the XPS spectrum of the S 2p core level that was obtained from the MUA/OT-Au sample. The S 2p/2 peak at 162 eV is characteristic of the sulfur in the MUA/OT-Au sample. Figure 1b shows the C 1s electron spectrum of the MUA/OT-Au sample characteristic of C-C bonds (284.8 eV) and C=O bonds (289.5 eV). Figure 1c shows the N 1s spectrum of the N-C bonds (288.0 eV) from the CYP2C9-MUA/OT-Au sample.

FIG. 1. a, XPS spectrum of the sulfur 2p (S 2p3/2) core level electrons obtained from the MUA/OT-Au sample corresponding to the S-Au bond (162.0 eV). b, XPS spectrum of the C 1s electrons obtained from the MUA/OT-Au sample characteristic of C-C bonds (284.8 eV) and C=O bonds (289.5 eV). c, XPS spectrum of the N 1s obtained from the CYP2C9-MUA/OT-Au sample ascribed to N-C = O bonds (403.0 eV). d, XPS spectrum of the C 1s electrons attributed to C-C bonds (284.8 eV), C-N peptide bonds (286.1 eV), and the N-C = O bonds (288.0 eV) from the CYP2C9-MUA/OT-Au sample.
the protein were observed in the CYP2C9-MUA/OT-Au sample. The N 1s peak at 0.403 eV in Fig. 1c corresponds to the amide linkages that are expected for the CYP2C9 peptide bonds and to the amide bonds between MUA and CYP2C9. The peak at 286.1 eV in Fig. 1d is assigned to the C-N peptide bonds of CYP2C9 and the MUA-CYP2C9 amide bonds. The C 1s peak at 288.0 eV is due to the O = C-N bond (Song et al., 1993). It is noteworthy that the peak at 289.5 eV, which was present in MUA/OT-Au before enzyme attachment (Fig. 1b), is not observed after attachment of CYP2C9 (Fig. 1d), suggesting amide bond formation between CYP2C9 and the MUA. Thus, the XPS spectra are consistent with the proposal that the CYP2C9 is covalently bonded to the MUA-functionalized gold surface.

Direct Electrochemistry of Immobilized CYP2C9 Enzyme in the Absence of Oxygen. Figure 2 shows the cyclic voltammograms obtained from a bare gold electrode (Fig. 2, curve a) and the MUA/OT-Au electrode (Fig. 2, curve b) in PBS containing 1 mM K$_3$[Fe(CN)$_6$] and 1 mM K$_4$[Fe(CN)$_6$] under anaerobic conditions. The CV exhibited a formal potential $E_f$ [eq. (1)] of 0.45 V (versus Ag/AgCl, 3M KCl). The formal potential $E_f$ is given by eq. 1.

$$E_f = \frac{E_{ox} + E_{re}}{2}$$

where $E_{ox}$ and $E_{re}$ are the oxidation and reduction peak potentials, respectively.

Figure 2 shows the cyclic voltammograms in 40 mM PBS solution containing 154 mM NaCl at a scan rate of 1.6 V/s under the nitrogen-saturated condition (dashed lines indicate the background current). b, the cathodic peak current (negative slope) and the anodic peak current (positive slope) as a function of scan rate from 500 to 1600 mV/s.

The peak currents (those above the background current) observed for the CYP2C9-MUA/OT-Au electrode under aerobic conditions was also obtained (data not shown) and was identical to the CV for the MUA/OT-Au electrode under anaerobic conditions (Bard and Faulkner, 2001). Furthermore, the SAM must be compact and uniform to efficiently block electron transfer (Diao et al., 1999). The CV of the MUA/OT-Au electrode under aerobic conditions was also obtained (data not shown) and was identical to the CV for the MUA/OT-Au electrode under the anaerobic condition (Fig. 2, curve b).

Cyclic voltammograms obtained from the electrode modified with the CYP2C9 enzyme under anaerobic conditions caused a well defined redox couple as shown in Fig. 3a. The data indicate direct electrochemistry of the covalently coupled CYP2C9 to the SAM-modified electrode. The CV exhibited a formal potential $E_f$ [eq. (1)] of 0.45 V (versus Ag/AgCl, 3M KCl). The peak currents (those above the background current) observed for the oxidation ($-0.42$ V) and reduction ($-0.49$ V) peaks were nearly identical. The peak difference ($\Delta E_p$) between $E_{ox}$ and $E_{re}$ is 70 mV (scan rate 1.6 V/s), which indicates a quasireversible single-electron redox reaction and is consistent with the reversible conversion of heme iron shown in eq. 4. This phenomenon has also been observed with other P450 isoenzymes such as CYP2B4 (Shumyantseva et al., 2004), CYP2E1 (Fantuzzi et al., 2004), P450 BM3 (Fantuzzi et al., 2006), CYP2C9 (Johnson et al., 2005), and CYP3A4 (Joseph et al., 2003).

$$\text{CYP2C9-Fe(III)} + e^- \rightleftharpoons \text{CYP2C9-Fe(II)} \quad (4)$$

Both the anodic and cathodic peak currents linearly increase with increasing scan rate from 0.5 to 1.6 V/s (Fig. 3b), suggesting that the voltammetric response is due to the surface-confined adsorbed redox molecules without any influence of protein diffusion away from or to the electrode surface (Bard and Faulkner, 2001; Myland and Oldham, 2005). It is notable that the peak width at a scan rate of 1.6 V/s (Fig. 3a) is close to the theoretical value of 90 mV for a typical single-electron wave of an adsorbed protein (Shukla et al., 2005). This peak width result is most likely reflective of the homogeneity in the conformation or orientation of the bonded CYP2C9 across the modified electrode surface, leading to an identical microscopic redox potential.

Determination of Enzyme Surface Coverage and Electron Transfer Rate. For redox-active molecules immobilized on an electrode surface, the peak current ($i_p$) is proportional to the number of redox-active sites (N) and the number of electrons transferred (n).

$$i_p \propto N \times n$$

The values of n and N can be determined by fitting the oxidation or reduction peak current as a function of scan rate (Fig. 3b) (Laviron, 1979). Using eq. 1, n was determined to be 0.72 and indicates that a single-electron-transfer reaction occurs in the immobilized CYP2C9 under anaerobic conditions (Bard and Faulkner, 2001). Furthermore, given n = 0.72, the surface coverage of active CYP2C9 molecules can be calculated and the result was $8.0 \times 10^{-13}$ mol/cm$^2$ (equivalent to $4.8 \times 10^{11}$ molecules/cm$^2$). This number is within a factor of 2 of our...
This is probably due to the fact that the amount of CYP2C9 in solution was larger than those obtained from the controlled potential electrolysis. Similar metabolite peaks from the solution-based incubations are obtained in the presence of 0.5 μM warfarin under oxygen-saturated conditions. Comparison of the traces in Fig. 5 shows that both CPR and phospholipids, and CYP2C9. The chromatogram shown in Fig. 4, curve a, is identical to that shown in Fig. 3a. In the absence of oxygen and warfarin, the catalytic cycle stalls after the reduction of Fe(III) to Fe(II) of CYP2C9, and a reversible CV of CYP2C9 is observed with an apparent formal potential of -0.45 V (eq. 4). Under anaerobic conditions, no variation in redox potential or the observed oxidation/reduction currents were observed in the presence of warfarin (data not shown). In the presence of oxygen and without the warfarin (Fig. 4, curve b), the oxidation peak is no longer observed and the current of the reduction peak, at approximately -0.49 V, increased. Under aerobic conditions, the addition of warfarin leads to an increase in the reduction current at -0.49 V (Fig. 4, curve c). Subsequent experiments revealed that this increase in reduction current was dependent on warfarin concentration.

Warfarin Metabolism Electro catalyzed by Immobilized CYP2C9. The electrochemical behavior of this system suggests that warfarin was being oxidized by the CYP2C9, possibly to the expected metabolite, 7-hydroxywarfarin. To confirm the electrocatalytic metabolism of warfarin at the CYP2C9-MUA/OT-Au electrode, a constant potential (-0.38 V) electrolysis was performed with the CYP2C9-MUA/OT-Au electrode in a solution containing warfarin (50 μM) and under aerobic conditions. After 2 h of controlled potential electrolysis, the solution was analyzed by high-performance liquid chromatography (HPLC) (Fig. 5, curve b). For comparison, CYP2C9-mediated warfarin metabolism was also performed in a solution containing NADPH, CPR, phospholipids, and CYP2C9. The chromatogram shown in Fig. 5, curve a, was obtained from the incubation of CYP2C9 and warfarin in solution. Comparison of the traces in Fig. 5 shows that both methods led to the formation of 7-hydroxywarfarin. It is noteworthy that the key major metabolites, observed under both conditions, are similar. Metabolite peaks from the solution-based incubations are larger than those obtained from the controlled potential electrolysis. This is probably due to the fact that the amount of CYP2C9 in solution (25 pmol) is considerably greater than that on the Au-SAM-CYP2C9 electrode (0.06 pmol, more than 400 times less than in solution).

Electrochemically Driven CYP2C9-Mediated Enzyme Kinetics of Warfarin. Figure 6 depicts the response of the reduction peak currents as a function of the warfarin concentration under oxygen-saturated conditions. The peak current increased with increasing warfarin concentrations, indicating good electrocatalytic activity of the immobilized CYP2C9. The peak current was linearly proportional to the warfarin concentration from 0 to 5 μM with a regression correlation coefficient (R²) of 0.97. In the linear range, the sensitivity of the current response to concentration of warfarin was estimated to be 64 μA · cm⁻² · μM⁻¹.

The apparent Michaelis-Menten constant (Kₘ) and iₘ (functionally equivalent to Vₘ) were used to evaluate the kinetics of warfarin catalysis by the immobilized CYP2C9 enzyme. By using the Michaelis-Menten Equation (eq. 3), the calculated Kₘ is 3 μM for the immobilized CYP2C9 on the electrode. The value for metabolism of warfarin in the present work is in the range estimated in the literature of Kₘ ~ 4 μM, obtained by the incubation of CYP2C9 and warfarin in the solution containing NADPH (Land and Böcker, 1995).

Discussion

The use of expressed, purified enzymes for both mechanistic and kinetic studies of P450 metabolism is common and can offer some advantages over the use of liver microsomes. At the same time, reconstituted enzyme systems (e.g., in artificial membranes of phospholipid vesicles) are a departure from the native membrane-bound environment and may permit interactions, such as P450 aggregation, that may not normally occur (Backes and Kelley, 2003). It is unfortunate that solution-based experiments do not allow easy control over these interactions and are not readily amenable to the direct study of drug transfer processes. To address the issue of controlling P450 reinsertion into artificial membranes, protein-protein interactions and the resulting effects, nanodiscs, were developed (Baybutt and Sligar, 2002). Nanodiscs have been used to colocalize CYP3A4 and CPR and mediate metabolism using NADPH. This approach permits study of isolated P450s but does not, as of this time, permit study of the effect of P450 aggregation (Denisov et al., 2007).

To overcome this issue of P450 catalysis requirements (NADPH/CPR or peroxides), allow for control of protein-protein interactions, and permit simultaneous control of electron transfer, an alternative
approach using P450 enzymes immobilized to a gold surface through a SAM has been developed (Gannett et al., 2006). This system is unique in that the bonded P450 (CYP2C9) is able to function with NADPH and CPR as the electron source and can be modified to study P450-P450 aggregation effects. Although this system can be developed for several applications including bioreactors for metabolite synthesis and biosensors for monitoring drug concentrations, the current work explores its use with an electrochemical means source for the potential study of electron transfer processes (Chen et al., 2002) (minus the NADPH/CPR components) and enzyme kinetics.

Previous work in other laboratories has involved P450s bound to a SAM electrostatically or immobilized in a matrix. In the current work, it was observed that bonding of the enzyme to a gold surface was required for electron transfer. The bonding probably occurs via the N terminus of the P450, although there are numerous surface lysine residues distributed over the entire surface of the CYP2C9 (Gannett et al., 2006). Previous work in our laboratory suggests that the surface lysines are not very accessible for bonding and that the N terminus is the most likely site for bonding to occur (Gannett et al., 2006). The redox behavior observed in the current work supports this proposal because it is consistent with homogeneous attachment, which requires each enzyme molecule to be attached in the same manner. If both surface lysines and the terminal residue were involved, very different redox behavior would be expected (Shukla et al., 2005).

It is interesting to note the redox potential observed for the bonded CYP2C9. For P450s in solution, the redox potential generally falls in the range of $-0.4$ to $-0.28$ V (Johnson et al., 2005). However, the redox potential typically shifts anodically when the P450 is immobilized. Shifts in redox potential can range as large as 0.4 V. In the present case, the observed redox potential is more similar to P450s in solution than immobilized. This suggests that the CYP2C9 is behaving as though it was free in solution and oriented as shown in Fig. 7.

As shown in Fig. 8, when electrons transfer between the electrode and heme iron, reduction of the heme iron occurs (step 2) and the P450 enters the catalytic cycle. In the absence of oxygen, only reduction from Fe(III) to Fe(II), as well as reoxidation (Fe(II)$\rightarrow$Fe(III)), should be possible (Fig. 8, step 2 and the reverse). In the presence of oxygen, reduction to Fe(II) will result in oxygen binding (Fig. 8, step 3). If no substrate is present, one of the three possible shunt processes (Fig. 8, step 3a, 4a, and/or 5a) will occur. Under these circumstances, the iron is
returned to the Fe(III) state and an oxidation current will not be detected. Because some shunt processes require more than one electron (Fig. 8, step 4a or 5a), the reduction current should increase relative to the CV data obtained in the absence of oxygen (Fig. 4, curve b). When both oxygen and a suitable substrate are present, metabolite production should be observed and electron consumption should further increase (Fig. 4, curve b) because both shunt (Fig. 8, steps 3a–5a) and metabolite formation (Fig. 8, steps 1–7) can now occur. The experimental observations are in complete agreement with these predictions, suggesting that the CYP2C9-MUA/OT-Au system and, with electrochemical provision of electrons, the CYP2C9-MUA/OT-Au electrode behave in a way that is similar to CYP2C9 in solution (metabolism with CPR and NADPH).

It is notable that the controlled potential electrolysis of warfarin resulted in formation of the expected 7-hydroxywarfarin metabolite. The amount of enzyme on the surface of the electrode was far less than is typically used for solution-based incubations; in the present case, approximately 0.06 pmol of enzyme was bonded to the surface. In contrast, the comparator solution incubations contained 25 pmol of enzyme, more than 400 times the amount on the gold-SAM electrode. The HPLC profiles of the solution and electrochemical incubation mixtures were not identical, and additional species are observed in the electrochemical incubations. Nevertheless, 7-hydroxywarfarin and a second metabolite with a slightly longer retention time are observed under either set of incubation conditions. There are many possibilities (e.g., salt concentration) that may be responsible for these differences, and elucidating the reason for these differences will be addressed in future work. Finally, after accounting for the relative amounts of CYP2C9 present and difference in incubation times, production of the 7-hydroxywarfarin metabolite in the electrochemical system is estimated, based on the amount of CYP2C9 and incubation time, to be 35 times greater than the solution system.

A final test of this electrochemical-CYP2C9-mediated enzyme metabolism and how well it mimics normal solution-based systems is the measurement of the kinetics of warfarin metabolism. We expect some difference in enzyme kinetic parameters, if for no other reason than a difference in the state of enzyme aggregation. Nevertheless, we find in our system a $K_{m}$ of 3 μM, a value that is in excellent agreement with the literature value of $K_{m}$ of ~4 μM (Land and Böcker, 1995). Analogous results were reported for CYP2E1 bonded directly to a gold electrode using surface cysteines, but it was not reported whether the CYP2E1 could metabolize the substrate using NADPH/CPR as the electron source (Fantuzzi et al., 2004).

In theory, bonding to the SAM may provide a pathway for electron passage from the outer surface and through the enzyme. Modeling of the enzyme bonded to the SAM via the N terminus suggests that the heme group of CYP2C9 is oriented in a fashion similar to bound gold electrode using surface cysteines, but it was not reported whether the heme relative to gold is of significant importance, it may inhibit or transfer if distance is the sole determinant. However, if orientation of the heme relative to gold is of significant importance, it may inhibit or block electron transfer.

In summary, direct electrochemistry of substrate (warfarin) was observed when CYP2C9 was bonded to a gold electrode through a self-assembled monolayer in the presence of oxygen. It is noteworthy that whereas the endogenous electron donor NADPH/CPR can serve as the source of electrons, the system also functions with the electrochemical provision of electrons. Metabolite production and kinetic measurements were consistent with solution-based incubations. Although purely speculative, the observation that electrons can transfer to the P450 from outside the protein from the gold surface suggests the possibility of multiple pathways (i.e., in addition to the putative CPR binding site) for electrons to move through the P450 and reduce the heme iron. The ability to control electron transfer, independent of P450 reductase, provides opportunities to potentially assist in identification of P450 cycle intermediates by controlling the progress of the P450 cycle, to evaluate the impact of P450 reductase binding on P450 conformation and cycle kinetics, and begin to address issues related to the contributions of cytochrome $b_{5}$ to P450 conformation and electron transfer.

Acknowledgments. The primary laboratory of origin was that of Professor Nianqiang Wu.

References


*Address correspondence to:* Peter M. Gannett, West Virginia University, Basic Pharmaceutical Sciences, Morgantown, WV 26506-9530. E-mail: pgannett@hsc.wvu.edu